Content type

Quick View: FDA’s Approval Of Dexcom’s Over-The-Counter Stelo Glucose Biosensor System Will Expand Access To Diabetes Management Devices

Healthcare / United States / Thu 07 Mar, 2024

The Latest: On March 5 2024, the US Food and Drug Administration (FDA) approved Dexcom’s Stelo Glucose Biosensor System, marking the first FDA approval of an over the counter (OTC) continuous glucose monitor (CGM). The device is an integrated CGM that is to be worn on the upper arm and lasts for up to 15 days before it needs to be replaced. It

Read More

Canada’s External Position To Improve Marginally In 2024

Country Risk / Canada / Tue 05 Mar, 2024

Key View

  • We forecast that Canada’s current account deficit will narrow to a 16-year low of 0.2% of GDP in 2024, from 0.6% in 2023.
  • This improvement will largely reflect a combination of softer import demand linked to a challenging domestic economic environment and a rebound in oil production.
  • Canada’s external sector continues to pose
Read More

Positive Outlook For J&J’s Multiple Myeloma Portfolio Following Latest Regulatory Developments

Pharmaceuticals / United States / Tue 27 Feb, 2024

Key View

  • Recent positive regulatory developments in Europe and the US will enhance J&J’s multiple myeloma drug portfolio. 
  • J&J’s multiple myeloma drug, Carvykti, will outperform Bristol-Myers Squibb’s Abecma, its closest competitor, further strengthening J&J’s oncology business.
  • The FDA’s growing caution of CAR T-cell therapies will pose
Read More
Download Indicator Summary
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Clearbit Form
 

Thank you. Your download link will be emailed to you shortly.